$60,000 of ARDELYX INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare ESRD benefit and chronic kidney disease management."
You can find more data on corporate lobbying on Quiver Quantitative.
ARDX Insider Trading Activity
ARDX insiders have traded $ARDX stock on the open market 20 times in the past 6 months. Of those trades, 6 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- DAVID M MOTT has made 6 purchases buying 1,158,106 shares for an estimated $4,784,606 and 0 sales.
- MICHAEL RAAB (President & CEO) has made 0 purchases and 6 sales selling 236,447 shares for an estimated $1,135,075.
- MIKE KELLIHER (See Remarks) sold 14,522 shares for an estimated $59,270
- JUSTIN A RENZ (Chief Financial Officer) has made 0 purchases and 2 sales selling 12,389 shares for an estimated $58,536.
- LAURA A WILLIAMS (Chief Medical Officer) has made 0 purchases and 2 sales selling 11,362 shares for an estimated $53,989.
- ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 10,283 shares for an estimated $48,584.
- ERIC DUANE FOSTER (Chief Commercial Officer) sold 2,507 shares for an estimated $10,232
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARDX Hedge Fund Activity
We have seen 118 institutional investors add shares of ARDX stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 8,268,990 shares (+7201.8%) to their portfolio in Q1 2025, for an estimated $40,600,740
- EVENTIDE ASSET MANAGEMENT, LLC removed 5,600,764 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $27,499,751
- MILLENNIUM MANAGEMENT LLC added 3,501,782 shares (+118.2%) to their portfolio in Q1 2025, for an estimated $17,193,749
- RUBRIC CAPITAL MANAGEMENT LP removed 1,706,485 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,378,841
- REDMILE GROUP, LLC removed 1,576,259 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $7,739,431
- JONES FINANCIAL COMPANIES LLLP removed 1,441,309 shares (-99.3%) from their portfolio in Q1 2025, for an estimated $7,076,827
- STATE STREET CORP removed 1,416,395 shares (-12.2%) from their portfolio in Q1 2025, for an estimated $6,954,499
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARDX Analyst Ratings
Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/18/2025
- Citigroup issued a "Buy" rating on 05/02/2025
- Scotiabank issued a "Sector Outperform" rating on 03/07/2025
- Ladenburg Thalmann issued a "Buy" rating on 03/07/2025
- Raymond James issued a "Strong Buy" rating on 02/21/2025
To track analyst ratings and price targets for ARDX, check out Quiver Quantitative's $ARDX forecast page.
ARDX Price Targets
Multiple analysts have issued price targets for $ARDX recently. We have seen 7 analysts offer price targets for $ARDX in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $10.0 on 06/18/2025
- Yigal Nochomovitz from Citigroup set a target price of $10.0 on 05/02/2025
- Aydin Huseynov from Ladenburg Thalmann set a target price of $11.0 on 03/07/2025
- Louise Chen from Scotiabank set a target price of $15.0 on 03/07/2025
- Ryan Deschner from Raymond James set a target price of $13.0 on 02/21/2025
- Christopher Raymond from Piper Sandler set a target price of $8.0 on 01/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
